#1 Clinical Trials Search in Europe

Phase 3 Study of Taletrectinib as Adjuvant Therapy in Patients with Completely Resected ROS1‑Positive Stage IB‑IIIA Non‑Small Cell Lung Cancer

3 1

What is this study about?

This study looks at patients with completely removed Non Small Cell Lung Cancer that has a specific genetic change called ROS1-fusion positive. After surgery, participants will receive either the oral medicine taletrectinib taken as a capsule once daily, or a matching placebo capsule that looks the same but contains no active drug.

The main aim is to see whether the medicine can keep the cancer from coming back compared with the placebo, measured by the length of time patients stay free of disease, known as DFS. Participants will take the study medication for a set period, return for regular check‑ups, and have routine tests such as scans and lab work to monitor their health.

In addition to tracking if the cancer returns, the study will also look at overall survival, which is how long participants live after treatment, referred to as OS, and whether the disease spreads to the CNS. Safety will be watched by recording any side effects using a standard grading system (CTCAE) and by performing simple heart rhythm checks (ECG). The study follows participants for several years to gather this information.

1 randomization and baseline assessments

after joining the study, the participant is assigned to receive either taletrectinib capsules or matching placebo capsules in a double‑blind manner, meaning the participant and the study team do not know which treatment is given.

baseline measurements are collected, including physical examination, vital signs, laboratory tests, electrocardiogram (ECG), and imaging to confirm that no cancer is detectable after surgery.

2 initiation of study medication

the participant begins taking the assigned study medication.

each dose consists of one oral capsule containing 400 mg of taletrectinib (or a matching placebo capsule).

the medication is taken by mouth according to the schedule defined by the study protocol.

3 regular safety monitoring visits

periodic clinic visits are scheduled to evaluate safety and tolerability.

during each visit, the participant undergoes a physical examination, vital‑sign measurement, laboratory testing, and an ECG to detect any adverse events.

4 assessment of disease‑free survival

the investigator evaluates whether cancer has returned, a measure known as disease‑free survival.

assessments are performed at predefined intervals throughout the study, including at 2, 3, 4, and 5 years after starting the medication.

5 long‑term follow‑up

the participant continues to be followed for up to five years to collect information on overall survival, central nervous system disease‑free survival, and any late‑occurring side effects.

blood samples may be taken to measure plasma concentrations of taletrectinib.

6 study completion or early discontinuation

the study ends for the participant when the predefined follow‑up period is completed, when disease recurrence is confirmed, or if the participant chooses to stop the medication.

final assessments are performed to document the participant’s status at the end of the trial.

Who Can Join the Study?

  • You have a confirmed diagnosis of non‑small cell lung cancer (NSCLC) that has been examined under a microscope, and the cancer is classified as stage IB, II, or IIIA according to the standard staging system.
  • Your tumor shows a specific genetic change called a ROS1 rearrangement, identified by a test performed in a laboratory that meets certified quality standards (CLIA‑certified or equivalent).
  • There is enough tumor tissue available so it can be tested again in a central laboratory to confirm the ROS1 result (if the same certified test was already done, extra confirmation is not needed, but tissue must still be sent for other studies).
  • You are 18 years of age or older.
  • Your overall health and ability to perform daily activities is rated as 0 or 1 on the ECOG performance status scale, meaning you are fully active or have only minor restrictions.
  • You have undergone surgery intended to cure the cancer, and the surgeon removed all visible tumor with negative margins (no cancer cells at the edge of the removed tissue).
  • You have fully recovered from the surgery:
    • If you did not receive additional chemotherapy, the surgery must have been performed at least 4 weeks and no more than 16 weeks before you could join the study.
    • If you did receive post‑surgery (adjuvant) chemotherapy, the surgery must have been performed at least 4 weeks and no more than 30 weeks before enrollment, the last chemotherapy dose must have been given at least 7 days earlier, and any side effects must have resolved to mild or none (grade 1 or lower according to CTCAE v5.0).

Who Cannot Join the Study?

  • Previous cancer treatments that are not allowed: having had radiation therapy after surgery for the current lung cancer, or any additional cancer drugs (except the standard platinum‑based chemotherapy) before the study starts.
  • Too many cycles of standard chemotherapy: having received more than four cycles of the usual platinum‑based chemotherapy regimen.
  • Immune checkpoint inhibitor (ICI) limits: if you received an ICI, you must have had no more than four cycles, and at least 12 weeks must have passed since the last dose, with any side effects from the ICI fully resolved.
  • Recent major surgery: having any major operation (including removal of the lung tumor) within four weeks before the study begins.
  • Limited lung surgery: having only a segmentectomy or wedge resection (partial removal of the tumor) unless you meet very specific stage criteria.
  • Use of strong CYP3A drugs or foods: taking medicines or eating substances that strongly affect the liver enzyme CYP3A within 14 days before randomization.
  • Recent investigational therapy: having taken any experimental drug for any condition (not just lung cancer) within the past six months.
  • Co‑mutations of EGFR or ALK: having genetic changes in the EGFR (epidermal growth factor receptor) or ALK (anaplastic lymphoma kinase) genes in addition to the ROS1 fusion.
  • History of other cancers: having had another cancer, except for non‑melanoma skin cancer, in‑situ cancer, or cancers that were cured and have been disease‑free for more than three years.
  • Significant heart disease: having serious cardiovascular problems (such as heart failure or recent heart attack) within three months before the study.
  • Uncontrolled high blood pressure: having blood pressure that is not well controlled by medication.
  • Serious heart rhythm problems: ongoing heart rhythm disturbances (grade 2 or higher), uncontrolled atrial fibrillation, a QT interval (a measure of heart electrical activity) longer than 470 ms, very slow heart rate (<45 beats per minute), or taking medicines that can cause a dangerous rhythm called Torsades de Pointes (TdP). Also, low levels of potassium, magnesium, or calcium must be corrected before randomization.
  • Active serious infections: having a current bacterial, fungal, or viral infection that is clinically important, including hepatitis B, hepatitis C, or HIV infection.
  • Interstitial lung disease or pneumonitis: having current or past interstitial lung disease, drug‑related lung inflammation, or radiation‑induced lung inflammation that required treatment with steroids.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
IRCCS Humanitas Research Hospital Rozzano Italy
Institut Gustave Roussy Villejuif France
Katholieke Universiteit te Leuven Leuven Belgium
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Azienda Ospedaliera Universitaria Universita’ Degli Studi Della Campania Luigi Vanvitelli Naples Italy
Hospital Universitario Y Politecnico La Fe Valencia Spain

Other Sites

Site Name City Country Status
Azienda Ospedaliero-Universitaria San Luigi Gonzaga Orbassano Italy
Centre Hospitalier Universitaire De Nantes Nantes France
Centre Hospitalier Universitaire De Rennes Rennes France
Hopital Beaujon Clichy France
Azienda Socio Sanitaria Locale N 2 Della Gallura Olbia Italy
Fondazione I.R.C.C.S. Istituto Neurologico Besta Milan Italy
Pius-Hospital Oldenburg Oldenburg In Holstein Germany
Justus-Liebig-Universitaet Giessen Giessen Germany
Thoraxklinik Heidelberg gGmbH Heidelberg Germany
Evangelische Lungenklinik Berlin Krankenhausbetriebs gGmbH Berlin Germany
Hospital Universitario Puerta De Hierro De Majadahonda Majadahonda Spain
Hospital Clinico Universitario Lozano Blesa Zaragoza Spain
Aaynbgbhhz Pcaarvog Hezlxqnx Dj Mwvcugtgb Marseille France
Cjmqcj Lxxh Bwanmh Lyon France
Inloqx Iptabthl Fvlgobcidlwyz Oxlyammfvje Rome Italy
Kqycrkum duc Uovikqqleuma Malrxjjm Ayg Munich Germany
Hmsfcgyo Vnji dszvarek Barcelona Spain
Inhzwujr Cqjqnj Dxxzayvylvydykzkg L'hospitalet De Llobregat Spain
Fhqzxirjj Pdbd La Itwbjwguuocpe Bephvjypn Dgq Hffymkft Uutqyxmhpbldp Ln Ppn Madrid Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Not yet recruiting
01.07.2026
France France
Not yet recruiting
01.07.2026
Germany Germany
Not yet recruiting
01.07.2026
Italy Italy
Not yet recruiting
01.07.2026
Spain Spain
Not yet recruiting
01.07.2026

Trial locations

Investigated drugs:

Taletrectinib is an oral medication taken in capsule form. In this study, it is being tested to see if it can help prevent the cancer from coming back after patients have had surgery to remove a ROS1‑fusion positive non‑small cell lung tumor. The drug is given to participants after their tumor has been completely removed, and researchers will compare how well it works to keep the disease from returning compared with a placebo.

Non‑Small Cell Lung Cancer – It is a type of lung tumor that begins in the larger airways and surrounding lung tissue. The cancer cells usually grow more slowly than those of small cell lung cancer. Over time the tumor can enlarge and invade nearby structures such as the bronchi and blood vessels. It may also spread through the bloodstream to other parts of the body, forming new growths. The disease often progresses in stages, starting with a localized mass and potentially advancing to regional and distant involvement.

Trial ID:
2025-521971-29-00
Protocol code:
AB-106-G319
NCT ID:
NCT07154706
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Greece Italy The Netherlands Poland +1

  • Zongertinib with cisplatin or carboplatin and pemetrexed, with or without pembrolizumab, for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Spain